10-Q: Dror Ortho-Design Q3 loss; adds $600k debentures

Pre-revenue aligner developer narrowed its quarterly loss, ended Q3 with $0.24M cash, and entered a $600k 0%-interest debenture financing in November with potential warrant coverage upon a future public offering.

Summary

• No revenue; net loss was $653,528 in Q3 2025 (vs. $1,826,935 in Q3 2024) and $1,988,989 for the nine months ended September 30, 2025 (vs. $4,642,188 in 2024).
• Cash at September 30, 2025 was $240,362 (down from $549,444 at December 31, 2024).
• Operating cash outflow was $1,409,082 for the nine months ended September 30, 2025; financing inflow from convertible promissory notes totaled $1,100,000.
• Current liabilities rose to $2,420,477, including $801,658 of convertible promissory notes (net), a $478,285 derivative liability, and a $520,000 Registration Rights Agreement liability.
• Stockholders’ deficit widened to $(2,317,813).
• R&D expense decreased to $151,456 in Q3 2025 (down 66% YoY); share-based compensation was $0 in Q3 2025 (vs. $543,101 in Q3 2024).
• New financing: on November 12, 2025 the company entered a Securities Purchase Agreement for $600,000 in 0% debentures due January 2026 (holders may extend in 60-day increments); purchasers have the right to buy an additional $200,000.
• Bridge structure: if a public offering occurs before maturity, debentures automatically convert at the offering price; associated warrants would be issued on offering terms with a 9.99% ownership cap.
• Going concern: management states substantial doubt about the company’s ability to continue as a going concern without additional capital.
• Strategy: preparing an updated AI-based aligner platform for FDA 510(k) submission; plans to spend approximately $2.5 million over the next 18 months on development, regulatory and IP.

Sentiment

Score: 3

Explanation: Improved quarterly loss and added bridge financing, but cash is very low, liabilities have risen, there is a going concern warning, and commercialization/regulatory milestones remain ahead.

Positives

• Quarterly net loss narrowed to $653,528 from $1,826,935 YoY on lower R&D and stock-based compensation.
• Secured bridge financing: $600,000 debentures on November 12, 2025 (0% interest, due January 2026) with an option for an additional $200,000.
• Reduced operating cash burn versus prior year: net cash used in operations of $1,409,082 for the nine months (vs. $2,178,725 in 2024).
• Flexibility to convert debt into equity at a future public offering price, aligning debtholders with equity outcomes and limiting immediate cash interest burden.

Negatives

• Very low cash balance of $240,362 at September 30, 2025 against $1,409,082 nine-month operating cash use.
• Going concern uncertainty explicitly disclosed; additional capital required to fund operations.
• Stockholders’ deficit widened to $(2,317,813); liabilities increased to $2,589,031.
• Debt overhang and derivative liabilities: $801,658 of convertible notes (net) and $478,285 derivative liability; $520,000 Registration Rights Agreement liability remains outstanding.
• No revenues; regulatory and commercialization timelines not yet defined.

Risks

• Substantial doubt about ability to continue as a going concern due to low cash and lack of revenue.
• Dependence on raising additional capital; no assurance of success or favorable terms.
• Regulatory risk: 510(k) clearance required for the updated platform; modifications may require new clearances.
• Competitive risk from established aligner companies with widely accepted products.
• Operational risk from conflicts in Israel; potential workforce disruptions and supply/logistics impacts.
• Market/liquidity risk: common stock not listed on a national exchange and has limited trading market.
• Contingent royalty obligations to the Israel Innovation Authority of approximately $1.19 million, payable only upon future sales.
• Debt and covenant constraints in debentures (negative covenants limit additional indebtedness, liens, dividends, etc.).

Future Outlook

Plans to continue development of its AI-based orthodontic platform and prepare a 510(k) submission; intends to spend approximately $2.5 million over the next 18 months on software/hardware development, regulatory processes and IP protection; exploring additional fundraising and has structured bridge debentures that convert automatically at the price of any future public offering before maturity.

Management Comments

• Management notes substantial doubt about the company’s ability to continue as a going concern without additional funding.
• Operations remain focused on preparing an updated platform for FDA 510(k) clearance; the first-generation system previously received 510(k) clearance in April 2020.
• R&D spending decreased due to reduced software development activities; share-based compensation declined as vesting completed.

Industry Context

The clear aligner market is dominated by well-capitalized incumbents and is highly regulated. New entrants must secure FDA clearances and demonstrate efficacy and comfort advantages. The company’s proposed sleep-time smart aligner aims to differentiate on convenience and pain reduction, but commercialization will require additional capital and clinical validation to compete credibly against established brands.

Comparison to Industry Standards

• Relative to Align Technology (ALGN), a profitable, scaled market leader, Dror is pre-revenue with a $0.24M cash balance and significant going-concern uncertainty.
• Typical early-stage medical device companies manage 12–18 months of runway; Dror’s nine-month operating cash use of $1.41M versus $0.24M cash at quarter-end implies limited runway absent near-term financing.
• Regulatory pathway (510(k)) aligns with standard U.S. requirements for Class II devices, but timing and clearance outcomes remain a key gating factor compared to peers with cleared products.

Legal Proceedings

• No material litigation pending or threatened as of the filing date.

Related Party Transactions

• Director consulting agreements: payments to directors for services (e.g., $10,262 in Q3 2025 to one director; $29,622 for nine months).
• Oriole Avenue Inc. (5%+ shareholder) consulting: cash of $145,000 over the service period (ended July 15, 2024) and warrants to purchase 10,454,500 shares at $0.033; no Q3 2025 payments.

Stakeholder Impact

• Shareholders face dilution risk from potential conversion of debentures and issuance of warrants upon a public offering.
• Creditors obtain negative covenants limiting additional indebtedness, dividends, and asset dispositions, potentially constraining flexibility.
• Employees and operations concentrated in Israel with risks of disruption due to regional conflict and potential military reserve call-ups.
• Vendors and partners may be affected by the company’s limited liquidity and the need for timely fundraising.

Next Steps

• Continue preparations to file a 510(k) submission for the updated platform.
• Pursue additional fundraising; November 2025 debenture investors may provide an additional $200,000.
• Maturity for November 2025 debentures in January 2026 unless extended by holders.
• Within 90 days of November 12, 2025, file an S-1 to register resale of warrant underlying shares per the purchase agreement.
• If a public offering is consummated before maturity, automatically convert outstanding debentures at the offering price and issue related warrants.

Key Dates

Recommendation

The company is pre-revenue with a low cash balance ($0.24M), a widening stockholders’ deficit, going concern uncertainty, rising liabilities (including convertible notes and derivative warrant liabilities), and no near-term revenue visibility. While bridge financing was secured, it introduces conversion and warrant overhang tied to a future public offering. Until additional capital is raised and a clear regulatory path is demonstrated, the risk/reward skews negative.

Keywords

Dror Ortho-Design, orthodontic aligner, AI dental platform, 510(k) clearance, convertible debenture, warrants, bridge financing, going concern, OTC Pink, Israel Innovation Authority